Skip to main content
. 2013 Nov 11;8(11):e78842. doi: 10.1371/journal.pone.0078842

Figure 4. Commercial inhibitors of Cdk4 protect neuronally differentiated PC12 cells against NGF deprivation.

Figure 4

Cells were subjected to NGF deprivation in presence and absence of commercially available small molecule inhibitors of Cdk4 for 20(A) graphical representation of percentage of viable cells following NGF deprivation in presence of indicated concentrations of commercially available Cdk4 inhibitor (Cdk4I1). Data represented as mean ± SEM of three independent experiments performed in duplicates. Theasterisks and hash denote statistically significant differences between indicated class:#p<0.05; *p<0.01. (B) Graphical representation of percentage of viable cells following NGF deprivation in presence of indicated concentrations of commercially available Cdk4 inhibitor Cdk4I2. Data represented as mean ± SEM of three independent experiments performed in duplicates. The asterisks denote statistically significant differences between indicated class:*p<0.01. (C) Representative phase contrast micrographs show retention of neuronal processes even after NGF deprivation in presence of commercially available Cdk4 inhibitors (Cdk4I1 & Cdk4I2).